277 related articles for article (PubMed ID: 28512671)
1. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
[No Abstract] [Full Text] [Related]
2. Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study.
Piaserico S; Gisondi P; De Simone C; Marinello E; Conti A; Amerio P; Peserico A
Acta Derm Venereol; 2016 Feb; 96(2):251-2. PubMed ID: 26270599
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of biological therapies in patients with psoriasis with alcoholic cirrhosis: a French retrospective study of 23 cases.
Begon E; Beneton N; Poiraud C; Droitcourt C; Jacobzone C; Vermersch-Langlin A; Descamps V; Perrot JL; Khemis A; Pallure V; Fougerousse AC; Sigal-Grinberg M; Schmutz JL; Goujon C; Reguiai Z;
Br J Dermatol; 2018 Aug; 179(2):512-513. PubMed ID: 29480522
[No Abstract] [Full Text] [Related]
4. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab.
Nakahara T; Konishi S; Yasukochi Y; Esaki H; Tsuji G; Kido-Nakahara M; Furue M
J Dermatol; 2019 May; 46(5):e157-e158. PubMed ID: 30353917
[No Abstract] [Full Text] [Related]
5. Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.
van Bezooijen JS; van Doorn MBA; Schreurs MWJ; Koch BCP; Te Velthuis H; Prens EP; van Gelder T
Ther Drug Monit; 2017 Aug; 39(4):379-386. PubMed ID: 28570371
[TBL] [Abstract][Full Text] [Related]
6. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
8. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.
Chen YC; Huang YT; Yang CC; Lai EC; Liu CH; Hsu CK; Wong TW; Chao SC; Sheu HM; Lee CN
PLoS One; 2020; 15(12):e0244620. PubMed ID: 33373425
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
[TBL] [Abstract][Full Text] [Related]
10. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
[TBL] [Abstract][Full Text] [Related]
11. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
[TBL] [Abstract][Full Text] [Related]
12. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
Feldman SR; Zhao Y; Zhou H; Herrera V; Tian H; Li Y
J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
[TBL] [Abstract][Full Text] [Related]
13. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
14. Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.
Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
Acta Derm Venereol; 2017 Jun; 97(6):705-710. PubMed ID: 28224166
[TBL] [Abstract][Full Text] [Related]
15. Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?
Gkini MA; Bewley AP
Dermatol Ther; 2018 Nov; 31(6):e12742. PubMed ID: 30221819
[No Abstract] [Full Text] [Related]
16. Update on TNF Inhibitors.
Kerdel FA
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S67-70. PubMed ID: 27526035
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
Atalay S; van den Reek JMPA; den Broeder AA; van Vugt LJ; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MA; van de Kerkhof PCM; Groenewoud HMM; Kievit W; de Jong EMGJ
JAMA Dermatol; 2020 Apr; 156(4):393-400. PubMed ID: 32049319
[TBL] [Abstract][Full Text] [Related]
18. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
[TBL] [Abstract][Full Text] [Related]
19. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
[TBL] [Abstract][Full Text] [Related]
20. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.
Busard CI; Menting SP; van Bezooijen JS; van den Reek JM; Hutten BA; Prens EP; de Jong EM; van Doorn MB; Spuls PI
Trials; 2017 Feb; 18(1):52. PubMed ID: 28148280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
